surmount-1 trial tirzepatide weight loss non-diabetic for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide vs semaglutide: A new
Description
For enhanced lifting and sculpting benefits, pair with professional in-office treatments
Alexander Shapsis
At the ESC Congress 2025, NovoNordisk revealed realworld data showing Wegovy (semaglutide 2.4mg) reduces major adverse cardiovascular events by 57% compared with tirzepatide in overweight/obese patients with established CVD and no diabetes.
It usually involves both sides
